Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT102 in MSLN-positive advanced solid tumors
NCT06717022Phase 1Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHT102 in solid tumor, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Dose Limiting Toxicities at 28 days. Started May 2024; status: recruiting.
02
Drugs
CHT102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06717022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717022.